The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: a translational study [ASCENT]

Stephen Clarke; Matthew Burge; Kynan Feeney; Peter Gibbs; Kristian Jones; Gavin Marx; Mark P. Molloy; Timothy Price; William H. H. Reece; Eva Segelov; Niall C. Tebbutt

doi:10.1371/journal.pone.0229900

The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: a translational study [ASCENT]

Stephen Clarke^*, Matthew Burge, Kynan Feeney, Peter Gibbs, Kristian Jones, Gavin Marx, Mark P. Molloy, Timothy Price, William H. H. Reece, Eva Segelov, Niall C. Tebbutt

^*Corresponding author for this work

Australian Proteome Analysis Facility (APAF)

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

53 Downloads (Pure)

Abstract

Background: In spite of demonstrating prognostic and possibly predictive benefit in retrospective cohorts and meta-analyses of cancer populations, including colorectal cancer (CRC), prospective evaluation of the relationship between neutrophil to lymphocyte ratio (NLR) and treatment outcomes in previously untreated mCRC patients receiving bevacizumab-based therapy has not yet been performed.

Methods: An open-label, single arm, multi-centre study. Patients received first-line bevacizumab plus XELOX or mFOLFOX6 (Phase-A) and continued bevacizumab plus FOLFIRI beyond first progression (Phase-B). Analyses included the association of NLR with phase A progression free survival (PFS) and overall survival (OS). A sub-study investigated the safety in patients with the primary in situ tumor. An exploratory sub-study examined relationships of circulating proteomic markers with PFS.

Results: Phase-A enrolled 128 patients; median age was 64 years (range: 26-84), 70 (55%) were female, 71 (56%) were PS-0 and 51 (40%) had primary in situ tumor. Fifty-three (41%) patients entered Phase-B. The median baseline (b) NLR was 3.2 (range: 1.5-20.4) with 32 (25%) patients having bNLR > 5. The PFS hazard ratio (HR) by bNLR > 5 versus ≤ 5 was 1.4 (95% CI: 0.9-2.2; p = 0.101). The median PFS was 9.2 months (95% CI: 7.9-10.8) for Phase-A and 6.7 months (95% CI: 3.0-8.2) for Phase-B. The HR for OS based on bNLR > 5 versus ≤ 5 was 1.6 (95% CI: 1.0-2.7; p = 0.052). The median OS was 25 months (95% CI: 19.2-29.7) for the full analysis set and 14.9 months for Phase-B. Baseline levels of nine proteomic markers showed a relationship with PFS. Treatment related toxicities were consistent with what has previously been published. There were 4 (3%) instances of GI perforation, of which, 3 (6%) occurred in the primary in situ tumor group.

Conclusions: Results from this study are aligned with the previously reported trend towards worse PFS and OS in patients with higher bNLR.

Original language	English
Article number	e0229900
Pages (from-to)	1-11
Number of pages	11
Journal	PLoS ONE
Volume	15
Issue number	3
DOIs	https://doi.org/10.1371/journal.pone.0229900
Publication status	Published - 6 Mar 2020

Bibliographical note

Copyright the Author(s) 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Access to Document

10.1371/journal.pone.0229900

Publisher version (open access)Final published version, 686 KBLicence: CC BY

Cite this

Clarke, S., Burge, M., Feeney, K., Gibbs, P., Jones, K., Marx, G., Molloy, M. P., Price, T., Reece, W. H. H., Segelov, E., & Tebbutt, N. C. (2020). The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: a translational study [ASCENT]. PLoS ONE, 15(3), 1-11. Article e0229900. https://doi.org/10.1371/journal.pone.0229900

@article{75a840492651486080d8beefdff9d132,

title = "The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: a translational study [ASCENT]",

abstract = "Background: In spite of demonstrating prognostic and possibly predictive benefit in retrospective cohorts and meta-analyses of cancer populations, including colorectal cancer (CRC), prospective evaluation of the relationship between neutrophil to lymphocyte ratio (NLR) and treatment outcomes in previously untreated mCRC patients receiving bevacizumab-based therapy has not yet been performed. Methods: An open-label, single arm, multi-centre study. Patients received first-line bevacizumab plus XELOX or mFOLFOX6 (Phase-A) and continued bevacizumab plus FOLFIRI beyond first progression (Phase-B). Analyses included the association of NLR with phase A progression free survival (PFS) and overall survival (OS). A sub-study investigated the safety in patients with the primary in situ tumor. An exploratory sub-study examined relationships of circulating proteomic markers with PFS. Results: Phase-A enrolled 128 patients; median age was 64 years (range: 26-84), 70 (55%) were female, 71 (56%) were PS-0 and 51 (40%) had primary in situ tumor. Fifty-three (41%) patients entered Phase-B. The median baseline (b) NLR was 3.2 (range: 1.5-20.4) with 32 (25%) patients having bNLR > 5. The PFS hazard ratio (HR) by bNLR > 5 versus ≤ 5 was 1.4 (95% CI: 0.9-2.2; p = 0.101). The median PFS was 9.2 months (95% CI: 7.9-10.8) for Phase-A and 6.7 months (95% CI: 3.0-8.2) for Phase-B. The HR for OS based on bNLR > 5 versus ≤ 5 was 1.6 (95% CI: 1.0-2.7; p = 0.052). The median OS was 25 months (95% CI: 19.2-29.7) for the full analysis set and 14.9 months for Phase-B. Baseline levels of nine proteomic markers showed a relationship with PFS. Treatment related toxicities were consistent with what has previously been published. There were 4 (3%) instances of GI perforation, of which, 3 (6%) occurred in the primary in situ tumor group. Conclusions: Results from this study are aligned with the previously reported trend towards worse PFS and OS in patients with higher bNLR.",

author = "Stephen Clarke and Matthew Burge and Kynan Feeney and Peter Gibbs and Kristian Jones and Gavin Marx and Molloy, {Mark P.} and Timothy Price and Reece, {William H. H.} and Eva Segelov and Tebbutt, {Niall C.}",

note = "Copyright the Author(s) 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher. ",

year = "2020",

month = mar,

day = "6",

doi = "10.1371/journal.pone.0229900",

language = "English",

volume = "15",

pages = "1--11",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "3",

}

TY - JOUR

T1 - The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab

T2 - a translational study [ASCENT]

AU - Clarke, Stephen

AU - Burge, Matthew

AU - Feeney, Kynan

AU - Gibbs, Peter

AU - Jones, Kristian

AU - Marx, Gavin

AU - Molloy, Mark P.

AU - Price, Timothy

AU - Reece, William H. H.

AU - Segelov, Eva

AU - Tebbutt, Niall C.

N1 - Copyright the Author(s) 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2020/3/6

Y1 - 2020/3/6

N2 - Background: In spite of demonstrating prognostic and possibly predictive benefit in retrospective cohorts and meta-analyses of cancer populations, including colorectal cancer (CRC), prospective evaluation of the relationship between neutrophil to lymphocyte ratio (NLR) and treatment outcomes in previously untreated mCRC patients receiving bevacizumab-based therapy has not yet been performed. Methods: An open-label, single arm, multi-centre study. Patients received first-line bevacizumab plus XELOX or mFOLFOX6 (Phase-A) and continued bevacizumab plus FOLFIRI beyond first progression (Phase-B). Analyses included the association of NLR with phase A progression free survival (PFS) and overall survival (OS). A sub-study investigated the safety in patients with the primary in situ tumor. An exploratory sub-study examined relationships of circulating proteomic markers with PFS. Results: Phase-A enrolled 128 patients; median age was 64 years (range: 26-84), 70 (55%) were female, 71 (56%) were PS-0 and 51 (40%) had primary in situ tumor. Fifty-three (41%) patients entered Phase-B. The median baseline (b) NLR was 3.2 (range: 1.5-20.4) with 32 (25%) patients having bNLR > 5. The PFS hazard ratio (HR) by bNLR > 5 versus ≤ 5 was 1.4 (95% CI: 0.9-2.2; p = 0.101). The median PFS was 9.2 months (95% CI: 7.9-10.8) for Phase-A and 6.7 months (95% CI: 3.0-8.2) for Phase-B. The HR for OS based on bNLR > 5 versus ≤ 5 was 1.6 (95% CI: 1.0-2.7; p = 0.052). The median OS was 25 months (95% CI: 19.2-29.7) for the full analysis set and 14.9 months for Phase-B. Baseline levels of nine proteomic markers showed a relationship with PFS. Treatment related toxicities were consistent with what has previously been published. There were 4 (3%) instances of GI perforation, of which, 3 (6%) occurred in the primary in situ tumor group. Conclusions: Results from this study are aligned with the previously reported trend towards worse PFS and OS in patients with higher bNLR.

AB - Background: In spite of demonstrating prognostic and possibly predictive benefit in retrospective cohorts and meta-analyses of cancer populations, including colorectal cancer (CRC), prospective evaluation of the relationship between neutrophil to lymphocyte ratio (NLR) and treatment outcomes in previously untreated mCRC patients receiving bevacizumab-based therapy has not yet been performed. Methods: An open-label, single arm, multi-centre study. Patients received first-line bevacizumab plus XELOX or mFOLFOX6 (Phase-A) and continued bevacizumab plus FOLFIRI beyond first progression (Phase-B). Analyses included the association of NLR with phase A progression free survival (PFS) and overall survival (OS). A sub-study investigated the safety in patients with the primary in situ tumor. An exploratory sub-study examined relationships of circulating proteomic markers with PFS. Results: Phase-A enrolled 128 patients; median age was 64 years (range: 26-84), 70 (55%) were female, 71 (56%) were PS-0 and 51 (40%) had primary in situ tumor. Fifty-three (41%) patients entered Phase-B. The median baseline (b) NLR was 3.2 (range: 1.5-20.4) with 32 (25%) patients having bNLR > 5. The PFS hazard ratio (HR) by bNLR > 5 versus ≤ 5 was 1.4 (95% CI: 0.9-2.2; p = 0.101). The median PFS was 9.2 months (95% CI: 7.9-10.8) for Phase-A and 6.7 months (95% CI: 3.0-8.2) for Phase-B. The HR for OS based on bNLR > 5 versus ≤ 5 was 1.6 (95% CI: 1.0-2.7; p = 0.052). The median OS was 25 months (95% CI: 19.2-29.7) for the full analysis set and 14.9 months for Phase-B. Baseline levels of nine proteomic markers showed a relationship with PFS. Treatment related toxicities were consistent with what has previously been published. There were 4 (3%) instances of GI perforation, of which, 3 (6%) occurred in the primary in situ tumor group. Conclusions: Results from this study are aligned with the previously reported trend towards worse PFS and OS in patients with higher bNLR.

UR - http://www.scopus.com/inward/record.url?scp=85081236003&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0229900

DO - 10.1371/journal.pone.0229900

M3 - Article

C2 - 32142532

AN - SCOPUS:85081236003

SN - 1932-6203

VL - 15

SP - 1

EP - 11

JO - PLoS ONE

JF - PLoS ONE

IS - 3

M1 - e0229900

ER -

The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: a translational study [ASCENT]

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this